Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.84 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.84 |
| ▸ | BRD2 | P25440 | 3/20 | 0.84 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.84 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.84 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.84 |
| ▸ | JAK2 | O60674 | 1/20 | 0.84 |
| ▸ | BRD1 | O95696 | 1/20 | 0.84 |
| ▸ | CCL2 | P13500 | 1/20 | 0.84 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.84 |
| ▸ | EP300 | Q09472 | 1/20 | 0.84 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.84 |
| ▸ | DNER | Q8NFT8 | 1/20 | 0.84 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.84 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.84 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.84 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.84 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.84 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.84 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25514131 | 0.91 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21349525 | 0.91 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881208 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881473 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL881227 | 0.91 | BRD4 (1.00) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL21320191 | 0.91 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL15984904 | 0.91 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL23660571 | 0.90 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL22973254 | 0.90 | BRD4 (0.87) | BRD4BRDTBRD2BRD3CREBBP | |
| SCHEMBL23660513 | 0.90 | BRD4 (0.84) | BRD4BRDTBRD2BRD3CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| WO-2015081280-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013033268-A2 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033269-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013033270-A2 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243322-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | BRDT, BRD2, BRD4 | BRD4 3/4885BRDT 1/4885BRD2 2/4885 |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRDT 1/4885BRD2 5/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | BRD4 2025/4885BRDT 1908/4885BRD2 3053/4885 |
| US-20140243321-A1 | BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | BRD4 2/4885BRDT 1/4885BRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.